BMRA

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2026 ended February 28, 2026. Key Highlights: 1. inFoods® IBS Real-World Data: Nearly 60% of Irritable Bowel Syndrome (“IBS”) Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with inFoods® IBS During the third quarter, Biomerica reported real-world data showing: 59.4% of patients achieved ≥30% reduction in abdominal pain 68.1% achieved ≥30% reduction in bloating — using the FDA-recognized responder endpoint consistent with Biomerica’s peer-reviewed randomized controlled trial These real-world findings build on a peer-reviewed, randomized controlled clinical trial published in Gastroenterology, conducted across five major academic centers including Mayo Clinic, Cleveland Clinic, and the University of Michigan, and Houston Methodist Hospital. That pivotal study demonstrated significantly greater abdominal pain relief in the treatment arm versus the sham diet arm (59.6% vs. 42.1%, p = 0.02). 2. CMS Establishes National Medicare Payment Rate for inFoods® IBS Test The Centers for Medicare & Medicaid Services (CMS) established a national Medicare payment rate of $300 for inFoods® IBS, effective January 1, 2026. This milestone provides reimbursement clarity and represents an important step toward expanding patient access to inFoods® IBS through the Medicare system. Biomerica and its lab partner are working with the appropriate Medicare Administrative Contractor to attain Medicare coverage for inFoods® IBS. 3. European Revenue Up 45% in the Quarter; hp+detect™ Receives UK Regulatory Registration Revenue from European customers grew 45% year-over-year in the third quarter, increasing from $198,000 to $287,000. Biomerica believes this growth reflects building commercial momentum on the continent. Subsequent to quarter end, Biomerica further strengthened its European position on two fronts: UK MHRA Registration: hp+detect™ received registration from the UK Medicines and Healthcare products Regulatory Agency, providing the regulatory foundation for commercial sales in the United Kingdom. First Commercial European Lab Order: Biomerica received its first commercial order for hp+dete...

Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights: Management Commentary Zack Irani, CEO said, "We are executing a deliberate strategic pivot from legacy, lower-margin products to higher-value, higher-margin diagnostic-guided therapy products. The current revenue softness reflects this transition, not fundamental business deterioration. With our fixed cost structure largely in place, we believe incremental revenue from inFoods® IBS and new partnerships such as Henry Schein as well as hp+detect™ opportunities should drive significant margin expansion. Additionally, our contract development and manufacturing organization (CDMO) expansion leverages existing infrastructure to generate higher-margin revenue while diversifying our revenue base." "While second quarter revenue reflected expected variability across our established product lines, Biomerica continued to strengthen its financial foundation through successful capital raising activities and disciplined cost management,” said Gary Lu, CFO of Biomerica. “Earlier in the fiscal year, the Company also received approximately $1.10 million in Employee Retention Credit (ERC) refunds, which, together with our financing initiatives, contributed to a $457,000 year-to-date improvement in working capital and an increase in our cash position to $2.5 million. As we advance key programs from development into commercialization, we are prudently reallocating resources, which resulted in a 27% reduction in research and development expenses, while continuing to invest in the commercial launch of high-value diagnostic programs, including inFoods® IBS and hp+detect™. We maintain access to additional capital through our existing shelf registration to support future growth initiatives.” Second Quarter and Year-to-Date Fiscal 2026 Financial Results Net sales for the second quarter of fiscal 2026 were $1.21 million, compared to $1.64 million in the prior year quarter. The decrease primarily reflects the absence of large initial distributor stocking orders in the Middle East and North Africa (“MENA...

Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, is proud to announce that its inFoods® IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a Henry Schein publication. The article, titled “Precision Medicine for IBS: A Novel, IBS-Specific Immune Response Guided Dietary Therapy”, presents comprehensive clinical and scientific insights into the company’s innovative approach to managing Irritable Bowel Syndrome (IBS). The publication details results from a randomized, multicenter, double-blind, placebo-controlled clinical trial evaluating the effectiveness of the inFoods® IBS test in identifying patient-specific dietary IBS triggers and guiding targeted food elimination to reduce IBS symptoms. Large Multicenter Study Demonstrates Clinically Meaningful Pain Reduction IBS affects an estimated 10% to 15% of adults in the United States and is known to significantly reduce quality of life and work productivity. Symptoms such as often severe abdominal pain, bloating, diarrhea, and constipation are frequently exacerbated by specific foods, yet identifying individual dietary triggers has historically relied on trial-and-error approaches. The inFoods IBS clinical trial analyzed 223 IBS patients across eight major U.S. academic medical centers including Mayo Clinic, Harvard Beth Israel Deaconess Medical Center, and Cleveland Clinic. Participants were tested for abnormal antibody responses to 18 IBS-specific foods using the inFoods® IBS assay and then randomized into two study arms: Treatment Group: Eliminated foods identified by the inFoods® IBS test as producing an abnormally elevated IgG immune response. Control Group: Followed a placebo (sham) diet eliminating foods for which the patient tested negative in the inFoods IBS test, matched in type and quantity to ensure blinding. Key Findings: 59.6% of patients in the inFoods IBS-guided diet (treatment group) achieved the FDA-defined target for abdominal pain reduction, compared to 42.1% in the control group for all IBS subclasses. Particularly strong results were observed in difficult-to-treat IBS subtypes: IBS-C: 67.1% respons...

Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational Efficiency Earnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), ("Biomerica" or the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter ended August 31, 2025. Key Highlights: First Quarter Fiscal 2026 Financial Results Net sales for the first quarter of fiscal 2026 were $1.4 million, compared to $1.8 million in the first quarter of fiscal year 2025. The decrease primarily reflects reduced retail market activity, the timing of international orders impacted by global tariff tensions, and decreased demand under certain contract manufacturing agreements and was partially offset by rising inFoods® IBS product sales. Despite the lower sales, gross profit increased, driven by a more favorable product mix and greater contribution from higher-margin contract manufacturing services. Operating expenses for the first quarter of fiscal 2026 decreased to $1.5 million, compared to $1.7 million in the first quarter of fiscal year 2025, highlighting Biomerica’s continued emphasis on cost discipline and streamlining operations. The reduction was primarily achieved through targeted savings across research, administrative, and manufacturing support functions. As a result, operating loss for the first quarter of fiscal 2026 improved to $1.1 million, compared to $1.4 million in the first quarter of fiscal year 2025. Other income for the quarter included a non-recurring tax credit, which contributed to a net profit of approximately $2,000 for the first quarter of fiscal 2026, compared to a net loss of $1.3 million in the first quarter of fiscal year 2025. Biomerica continues to prioritize operational efficiency, strengthen its balance sheet, and invest selectively in core diagnostic programs that support long-term profitability. About inFoods® IBS inFoods® IBS is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and...

$1.3 Million in Operating Expense Reductions Achieved– Operating Loss Improves 19% Year-Over-Year Resilient Portfolio Performance with International Sales Despite Global Economic Uncertainties Cash Used in Operating Activities Reduced to $3.8 Million vs. $5.3 Million in the Prior Year, Reflecting Stronger Operating Discipline IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2025 (Fiscal 2025). The Company reported net sales of $5.3 million, compared to $5.4 million in the prior year. Revenue was modestly lower due to global tariff-related uncertainties, which caused certain international customers to delay orders, and a shift in product mix with fewer over-the-counter (OTC) retail sales during the fourth quarter. These headwinds were partially offset with increased sales from inFoods® IBS. Gross profit for the year was $498,000, versus $611,000 in the prior year, reflecting the impact of the macro-economic events on revenue and product mix. Cash used in operating activities improved significantly to $3.8 million, compared to $5.3 million in the prior year, a $1.5 million improvement driven by operating efficiencies and disciplined expense management. Through disciplined cost management, Biomerica reduced selling, general and administrative expenses to $4.6 million, compared to $5.5 million in the prior year and reduced research and development expenses to $1.0 million, compared to $1.5 million in the prior year. In total, operating expenses declined by more than $1.3 million, delivering on the cost-reduction goals announced at the beginning of the fiscal year. As a result, operating loss improved to $5.1 million, compared to $6.4 million in the prior year – a 19% year-over-year improvement, despite revenue headwinds. Strategic Growth Areas: Biomerica is actively working in three key areas to drive revenue growth: inFoods® IBS Opportunities – Insurance Reimbursement: The American Medical Association CPT Editorial Panel has issued a Proprietary Laboratory Analyses (PLA) code for Biomerica’s inFoods® IBS test, advancing the pathway for reimbursement and broader access. EZ Detect™ and Other At-Home Tests in the MENA Region: Continued regulatory clearances and expanded distribution partnerships across the Middle East and North Africa; Biomerica is also pursuing...

Landmark Peer-Reviewed Study Demonstrates Effectiveness of Personalized Dietary Therapy for IBS Patients Using inFoods® IBS Test. Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS. Study results suggest inFoods IBS could be particularly beneficial for IBS-M patients, a population with no current FDA-approved drug treatments. IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced diagnostic-guided therapies, today announced that data from its pivotal clinical trial evaluating the inFoods® IBS test in treating IBS sufferers has been published in the June 2025 issue of Gastroenterology, the official journal of the American Gastroenterological Association and the highest-impact publication in the GI field. The randomized, multicenter, double-blind, placebo-controlled trial demonstrated that patients with Irritable Bowel Syndrome (IBS) experienced statistically significant improvement in symptoms—particularly abdominal pain and bloating—when following a personalized elimination diet guided by the inFoods IBS test. The test identifies specific foods that provoke an abnormal immune response, believed to be a key trigger of IBS symptoms. “This publication in Gastroenterology reinforces the scientific rigor, statistical significance and clinical impact of the inFoods IBS approach for treating patients,” said Zack Irani-Cohen, CEO of Biomerica. “It marks a major milestone in precision nutrition as a non-drug treatment pathway for IBS.” Key Findings Highlighted in Gastroenterology The trial included 238 patients across eight U.S. academic centers (including Mayo Clinic, Clevland Clinic and Univ. of Michigan), comparing outcomes between a treatment group who eliminated foods identified by the inFoods IBS test versus a control group following a placebo “sham” diet. 59.6% of patients in the treatment group achieved the FDA responder definition for abdominal pain reduction, compared to 42.2% in the control group Among patients with IBS-C, 67.1% in the treatment arm reached this benchmark vs. 35.8% in controls Among those with IBS-M, 66.0% in the treatment group met the target vs. 29.5% in controls These results suggest inFoods IBS could be particularly beneficial for IBS-M patients, an underserved grou...

Revenue: US$1.12m (up 10.0% from 3Q 2024). Net loss: US$1.16m (loss narrowed by 39% from 3Q 2024). US$0.061 loss per share (improved from US$0.11 loss in 3Q 2024). We've discovered 5 warning signs about Biomerica. View them for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Biomerica shares are down 6.5% from a week ago. It is worth noting though that we have found 5 warning signs for Biomerica (4 are potentially serious!) that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Total Revenue Increases 10% Year-Over-Year Delivers Improved Gross Margins, Achieves Annual Cost Savings Target Early, and Reduces Cash Burn Over 55% IRVINE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the third quarter of fiscal 2025 ended February 28, 2025. Key Highlights: 1. Fortel® PSA Screening Test Approved by UAE Ministry of Health & Prevention:Biomerica’s Fortel® Prostate Specific Antigen (PSA) Screening Test has received regulatory approval from the United Arab Emirates Ministry of Health & Prevention (MOHAP). The Fortel® test offers fast, accurate PSA results in just 10 minutes using a simple finger-prick blood sample. By enabling earlier detection of prostate cancer and other prostate conditions, this easy-to-use diagnostic tool aims to enhance preventative care, reduce pressure on healthcare systems, and support improved patient outcomes. 2. inFoods® IBS Clinical Trial Results Published in Gastroenterology:New clinical data published in Gastroenterology, the leading peer-reviewed journal for gastrointestinal medicine, demonstrated that patients with Irritable Bowel Syndrome (IBS) experienced statistically significant reductions in abdominal pain and bloating when following a personalized diet therapy plan guided by Biomerica’s inFoods® IBS test. Unlike other IBS products, inFoods® IBS uniquely identifies specific foods that trigger elevated Immunoglobulin G (IgG) responses—a marker of inflammation linked to IBS symptoms—using a 95% confidence interval for each food in the panel. IBS affects an estimated 10%–15% of adults in the U.S. and contributes to reduced quality of life and productivity. The findings support the role of personalized food-guided therapy as a meaningful intervention for IBS management. 3. CE-IVDR Certification Achieved for Food Intolerance Products Targeting Ulcerative Colitis:Biomerica’s new food intolerance products targeting Ulcerative Colitis have been awarded CE-marking under the European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR), a stringent regulatory framework designed to enhance diagnostic safety and performance across Europe. This IVDR certification highlights Biomerica’s continued leadership in developing non-invasive, personalized diagnosti...